Literature DB >> 33531151

Multi-drug resistant tuberculosis, ten years later.

José Antonio Caminero Luna1, Guillermo Pérez Mendoza2, Felipe Rodríguez de Castro2.   

Abstract

Drug-resistant tuberculosis, especially those with resistance to rifampicin (RR-TB), has become one of the main obstacles to achieving the dream of eradicating tuberculosis. Furthermore, it is necessary to combine three or four different drugs in the attempt to cure TB, however, unfortunately, there are few available that can be considered genuinely effective. Fortunately, the notable worldwide increase in RR-TB in recent years has led to the investment of resources in the development of new drugs for TB, and other drugs investigated for other diseases have been successfully tested on TB. This has resulted in a clear change in the clinical management of these patients over the last 3-4 years, and it is now easier to design therapeutic regimens and achieve higher success rates. All these changes are updated in this review.
Copyright © 2020 Elsevier España, S.L.U. All rights reserved.

Entities:  

Keywords:  Drug-resistant tuberculosis; Extensively drug-resistant tuberculosis; MDR-TB; Multi-drug resistant tuberculosis; TB extensamente fármaco resistente; TB-MDR; TB-XDR; Tratamiento; Treatment; Tuberculosis; Tuberculosis con resistencia a fármacos; Tuberculosis multi-resistente; XDR-TB

Mesh:

Substances:

Year:  2021        PMID: 33531151     DOI: 10.1016/j.medcli.2020.08.018

Source DB:  PubMed          Journal:  Med Clin (Barc)        ISSN: 0025-7753            Impact factor:   1.725


  1 in total

1.  Factors contributing to the high prevalence of multidrug-resistance/Rifampicin-resistance in patients with tuberculosis: an epidemiological cross sectional and qualitative study from Khabarovsk krai region of Russia.

Authors:  Ilia Bykov; Olga Dyachenko; Pavel Ratmanov; Huan Liu; Libo Liang; Qunhong Wu
Journal:  BMC Infect Dis       Date:  2022-07-13       Impact factor: 3.667

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.